Elucidata Corporation

elucidata.io

Recognized as the 'Most Innovative Biotech Company, 2024' by Fast Company! Even today, early R&D, precision diagnostics, and translational biomarker teams spend about 80% of their time wrangling data. Elucidata's mission is to empower scientists in the life sciences field by reclaiming every valuable hour for their research endeavors. Elucidata’s data harmonization platform, Polly, helps research teams make multi-modal biomedical data machine learning ready. Each dataset on Polly is processed consistently using pipelines of your choice, is custom curated with granular annotations, and undergoes robust QA/QC checks to ensure the highest data quality standards. Polly transforms multi-modal and multi-source biomedical data (omics, assay, real-world data, clinical & EHR data, and CRO data) into a unified data model. With our 10x faster LLM-powered curation and human-in-the-loop model to achieve 99.99% accuracy, we are fast-tracking time to analysis. Today, Polly is facilitating use cases like patient stratification, biomarker discovery, target ID & validation, data management, and development of clinical and commercial pipelines across Pfizer, Janssen Pharmaceuticals, NextGen Jane, and IMBDx, and over 35 premier biopharma companies and research labs. Headquartered in San Francisco, we are a 120+ multi-disciplinary team of experts based across the US and India. In September 2022, we raised $16 million in our Series A round led by Eight Roads and F-Prime along with our existing investors Hyperplane and IvyCap. Write to us at info@elucidata.io for queries. To talk to us, visit: https://www.elucidata.io/book-a-meeting For more information, visit: https://www.elucidata.io/ Visit our offices - San Francisco Headquarters: 114 Sansome Street, Suite 250 San Francisco, CA 94104 Boston Office: 625 Massachusetts Avenue Cambridge, MA 02139 R&D Hubs, India - Delhi and Bangalore.